companydata.dkcompanydata.dk

AKI Therapeutics A/S: Financial statements 2025

CVR: 37509736

Source: annual report 2025, Danish Business Authority

01/01/2025 – 31/12/2025

AKI Therapeutics A/S (CVR 37509736) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,593,852,000 compared with DKK -1,960,091 the year before. Equity in the 2025 report amounted to DKK 551,898,000. The solvency ratio was 33.7%.

Revenue
DKK 0
Profit/Loss
DKK -1,593,852,000
Equity
DKK 551,898,000
Total Assets
DKK 1,639,948,000

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
202500-1.6B551.9M-
202400-2M807K-
202300-1.7M747K-
202200-1.1M2.5M-
20210-12K-1.5M3.6M-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is AKI Therapeutics A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2025

AKI Therapeutics A/S: The 2024 annual report is outJun 30, 2025

AKI Therapeutics A/S has published its annual report for 2024. Revenue came to DKK 0, and the net result was DKK -1,960,091.

About AKI Therapeutics A/S

AKI Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named AKI Therapeutics ApS and Renoguard ApS. The management consists of Sigbjørn Georg Nielsen Kjærgård. The board consists of Charlotte Pahl, Christian Vinding Thomsen and Lars Otto Uttenthal. The company's owners include NIELS ERIK JESPERSEN HOLDING ApS, Beier Holding ApS and FINANSMANAGEMENT ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,593,852,000 compared with DKK -1,960,091 the year before. Equity in the 2025 report amounted to DKK 551,898,000.

Source: annual report 2025, Danish Business Authority